Neilson, Aileen R.Jones, Gareth T.Macfarlane, Gary J.Pathan, Ejaz M.McNamee, Paul2023-01-062023-01-062022-11Neilson, A R, Jones, G T, Macfarlane, G J, Pathan, E M & McNamee, P 2022, 'Generating EQ-5D-5L health utility scores from BASDAI and BASFI : a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data', European Journal of Health Economics, vol. 23, pp. 1357-1369. https://doi.org/10.1007/s10198-022-01429-x1618-7598ORCID: /0000-0003-0016-7591/work/106160785ORCID: /0000-0003-2322-3314/work/106161205https://hdl.handle.net/2164/19802Acknowledgements We are grateful to the staff of the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis. Claudia Zabke, Maureen Heddle, Nafeesa Nazlee and Barry Morris, and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritis.php#panel1011. Funding The British Society for Rheumatology Biologics Register in Ankylosing. Spondylitis (BSRBR-AS) is funded by the British Society for Rheumatology (BSR), which in turn has received funding from the manufacturers of the biologic therapies included in the study (Abbvie, Pfizer and UCB). Pharmaceutical companies providing funds to BSR do not have a role in the oversight of the study, but they do receive advance notice of publications on which they can comment. They do not have access to the data collected but can request analyses of the data, for which additional funds are provided.131313199engmixture modelsutility mappingresponse mappingEQ-5D-5LBASDAI/BASFIaxial spondyloarthritisR MedicineOtherBSRBR-ASSupplementary InformationRJournal article10.1007/s10198-022-01429-x23